WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1992012178) PROTEIN WITH HUMAN CHORIOGONADOTROPIN INHIBITORY EFFECT
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/1992/012178    International Application No.:    PCT/US1991/009642
Publication Date: 23.07.1992 International Filing Date: 19.12.1991
IPC:
A61K 38/00 (2006.01), C07K 14/47 (2006.01), C07K 14/575 (2006.01)
Applicants: CEDARS-SINAI MEDICAL CENTER [US/US]; 8700 Beverly Boulevard, Los Angeles, CA 90048 (US)
Inventors: BRAUNSTEIN, Glenn, David; (US).
REN, Song-Guang; (US)
Agent: KWASIGROCH, Lois, M.; 611 West Sixth Street, 34th Floor, Los Angeles, CA 90017 (US)
Priority Data:
639,249 28.12.1990 US
806,914 13.12.1991 US
Title (EN) PROTEIN WITH HUMAN CHORIOGONADOTROPIN INHIBITORY EFFECT
(FR) PROTEINE AYANT UN EFFET INHIBITEUR SUR LA CHORIOGONADOTROPINE HUMAINE
Abstract: front page image
(EN)A substance having an inhibitory effect on the production of human choriogonadotropin (hCG) is described, which comprises a protein isolated from human decidual cells with a preliminary amino acid analysis and a molecular weight of about 7,000 to about 10,000 daltons, and useful for use in inhibiting production of hCG $i(in vivo) or $i(in vitro), may be measured as an indication of a cause of hCG inhibition, or used in the treatment of hCG-secreting tumors.
(FR)Substance ayant un effet inhibiteur sur la production de choriogonadotropine humaine (hCG), comprenant une protéine isolée à partir de cellules déciduales humaines ayant une analyse d'acide aminé préliminaire ainsi qu'une masse moléculaire comprise entre 7000 et environ 10000 daltons, et utilisée pour inhiber la production de hCG $i(in vivo) ou $i(in vitro), dont la mesure fournit une indication d'une cause d'inhibition de hCG, ou pouvant être utilisée dans le traitement de tumeurs secrétant de la hCG.
Designated States: AU, CA, JP.
European Patent Office (AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE).
Publication Language: English (EN)
Filing Language: English (EN)